Dr. William Pao presents this patient advocacy webinar on the history of lung cancer treatments and lung cancer drug development in the era of precision medicine. The webinar includes a review of how genomic testing, targeted therapies, immunotherapy, and acquired drug resistance are shaping the development of new drugs. This presentation is part of the IASLC STARS (Supportive Training for Advocates on Research and Science) program for Patient Research Advocates and anyone whose life is impacted by lung cancer. 

Thank you to our Partners & Sponsors: 

                                   

This presentation is part of the IASLC STARS (Supportive Training for Advocates on Research and Science) program for Patient Research Advocates and is open to anyone interested in these topics, or anyone whose life is impacted by lung cancer.

Upon completion of this activity, the participants should be able to: 

• Understand the history of precision medicine related to lung cancer
• Gain increased confidence in discussing precision medicine with the lung cancer community

Moderator:

• Janet Freeman-Daily, MS, Eng, Lung Cancer Patient and Research Advocate

Presenter:

• William Pao, MD, PhD, Head of Pharma Research adn Early Development (pRED)

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need assistance with this activity, please email: education@iaslc.org.